Streetbeat News

BTMD

biote Corp.

Industry

Medical - Care Facilities

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Open

6.55

Mkt cap

346M

Volume

58K

High

6.55

P/E Ratio

21.97

52-wk high

8.44

Low

6.21

Div yield

N/A

52-wk low

3.65

Analysts have set a mean price target for biote Corp. (BTMD) that suggests a potential 43.9% upside. Despite the mixed reliability of price targets, the consensus on raising earnings estimates indicates a positive outlook for BTMD.

Portfolio Pulse from

December 04, 2024 | 4:15 pm

The article discusses whether investors are undervaluing biote Corp. (BTMD) by focusing on the Zacks Rank system, which emphasizes earnings estimates and revisions. It highlights the importance of value, growth, and momentum trends in identifying strong stock picks.

Portfolio Pulse from

November 29, 2024 | 4:00 pm

biote Corp. (BTMD) has formed a hammer chart pattern, suggesting potential support and a possible trend reversal. This is supported by upward revisions in earnings estimates.

Portfolio Pulse from

November 22, 2024 | 4:15 pm

Wall Street analysts predict a 77% upside for biote Corp. (BTMD) based on average price targets. Positive earnings estimate revisions could support this potential increase.

Portfolio Pulse from

November 18, 2024 | 4:15 pm

The article discusses whether Biote Corp. (BTMD) stock is currently undervalued, focusing on the Zacks Rank system which uses earnings estimates and revisions to identify strong stocks. The analysis also considers value, growth, and momentum trends.

Portfolio Pulse from

November 13, 2024 | 4:00 pm

biote Corp. (NASDAQ:BTMD) held its Q3 2024 earnings call on November 12, 2024. Key participants included CEO Terry Weber and CFO Bob Peterson, with analysts from Cowen, B. Riley, Jefferies, Truist Securities, and ROTH Capital Partners attending.

Portfolio Pulse from

November 13, 2024 | 8:15 am

Biote Corp. (BTMD) reported Q3 earnings of $0.33 per share, surpassing the Zacks Consensus Estimate of $0.09 per share. This marks a significant improvement from a loss of $0.11 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 12:30 am

Biote shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:35 pm

Biote has reiterated its 2024 financial guidance, projecting revenues between $200M and $204M, with an estimated $202.049M. The company expects accelerated growth in the second half of the year and plans to moderate operating expenses.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:56 pm

Biote (NASDAQ:BTMD) reported Q2 2024 GAAP EPS of $(0.19), missing the $0.09 estimate by 311.11%. Sales were $49.169M, slightly beating the $49.062M estimate. EPS improved by 24% YoY, while sales decreased by 0.18% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.